Compare Stocks: ORKA, INCY, BNTX, and GMAB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$98.46 -2.4%	$97.75	$79.52 ▼ $124.00	$24.90B	1.29	1.10 million shs	1.04 million shs
GMAB Genmab A/S	$34.75 -1.3%	$31.75	$23.62 ▼ $35.66	$21.68B	0.84	1.96 million shs	2.51 million shs
INCY Incyte	$124.64 -1.8%	$122.95	$81.09 ▼ $132.60	$25.26B	0.77	1.72 million shs	1.53 million shs
ORKA Oruka Therapeutics	$89.93 -4.9%	$96.72	$14.89 ▼ $115.51	$5.95B	-0.34	1.10 million shs	1.99 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+2.93%	+4.32%	-13.47%	+11.82%	+2.18%
GMAB Genmab A/S	+1.53%	+3.13%	+5.29%	+36.19%	+23.15%
INCY Incyte	+1.83%	+4.26%	-0.69%	+17.03%	+49.81%
ORKA Oruka Therapeutics	+1.25%	+2.55%	-12.42%	+15.07%	+452.37%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$98.46 -2.4%	$97.75	$79.52 ▼ $124.00	$24.90B	1.29	1.10 million shs	1.04 million shs
GMAB Genmab A/S	$34.75 -1.3%	$31.75	$23.62 ▼ $35.66	$21.68B	0.84	1.96 million shs	2.51 million shs
INCY Incyte	$124.64 -1.8%	$122.95	$81.09 ▼ $132.60	$25.26B	0.77	1.72 million shs	1.53 million shs
ORKA Oruka Therapeutics	$89.93 -4.9%	$96.72	$14.89 ▼ $115.51	$5.95B	-0.34	1.10 million shs	1.99 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+2.93%	+4.32%	-13.47%	+11.82%	+2.18%
GMAB Genmab A/S	+1.53%	+3.13%	+5.29%	+36.19%	+23.15%
INCY Incyte	+1.83%	+4.26%	-0.69%	+17.03%	+49.81%
ORKA Oruka Therapeutics	+1.25%	+2.55%	-12.42%	+15.07%	+452.37%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.68	Moderate Buy	$126.00	27.25% Upside
GMAB Genmab A/S	2.85	Moderate Buy	$39.50	13.32% Upside
INCY Incyte	2.52	Moderate Buy	$124.05	-0.68% Downside
ORKA Oruka Therapeutics	2.82	Moderate Buy	$133.00	46.74% Upside

Current Analyst Ratings Breakdown

Latest ORKA, INCY, BNTX, and GMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	INCY Incyte	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sector Perform	$109.00
9/16/2026	BNTX BioNTech	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/16/2026	BNTX BioNTech	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$140.00
9/14/2026	GMAB Genmab A/S	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
9/11/2026	INCY Incyte	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/8/2026	BNTX BioNTech	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$128.00 ➝ $105.00
9/3/2026	ORKA Oruka Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$120.00
9/3/2026	ORKA Oruka Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
9/1/2026	GMAB Genmab A/S	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
9/1/2026	INCY Incyte	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
8/31/2026	BNTX BioNTech	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$142.00 ➝ $136.00

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$3.25B	7.71	$1.35 per share	73.40	$96.59 per share	1.03
GMAB Genmab A/S	$3.72B	5.84	$1.62 per share	21.55	$9.10 per share	3.83
INCY Incyte	$5.14B	4.92	$6.19 per share	20.17	$26.32 per share	4.75
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	$9.69 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$1.29B	-$7.83	N/A	N/A	N/A	-63.54%	-6.86%	-6.00%	11/3/2026 (Estimated)
GMAB Genmab A/S	$963M	$1.27	27.45	22.20	1.88	19.08%	14.89%	7.73%	11/5/2026 (Estimated)
INCY Incyte	$1.29B	$7.85	15.92	15.75	3.62	27.71%	29.93%	22.88%	10/27/2026 (Estimated)
ORKA Oruka Therapeutics	-$105.43M	-$2.03	N/A	N/A	N/A	N/A	-21.65%	-20.88%	11/11/2026 (Estimated)

Latest ORKA, INCY, BNTX, and GMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	ORKA Oruka Therapeutics	-$0.5125	-$0.55	-$0.0375	-$0.55	N/A	N/A
8/6/2026	Q2 2026	GMAB Genmab A/S	$0.37	$0.54	+$0.17	$0.4910	$1.12 billion	$1.16 billion
8/4/2026	Q2 2026	BNTX BioNTech	-$2.3983	-$2.5340	-$0.1357	-$3.70	$180.18 million	$122.31 million
7/28/2026	Q2 2026	INCY Incyte	$2.15	$3.09	+$0.94	$2.81	$1.50 billion	$1.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	7.85	7.80
GMAB Genmab A/S	0.81	2.46	2.44
INCY Incyte	N/A	4.59	4.51
ORKA Oruka Therapeutics	N/A	38.51	38.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
GMAB Genmab A/S	7.07%
INCY Incyte	96.97%
ORKA Oruka Therapeutics	56.44%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
GMAB Genmab A/S	1.54%
INCY Incyte	16.20%
ORKA Oruka Therapeutics	23.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
GMAB Genmab A/S	3,029	623.78 million	614.17 million	Optionable
INCY Incyte	2,844	202.70 million	169.86 million	Optionable
ORKA Oruka Therapeutics	68	66.21 million	50.66 million	N/A

ORKA, INCY, BNTX, and GMAB Headlines

Recent News About These Companies

Oruka Therapeutics (NASDAQ:ORKA) Shares Down 7.4% - Here's Why

4 hours ago | marketbeat.com

Oruka's ORKA-001 shows deepening psoriasis response at week 28

4 hours ago | streetinsider.com

Oruka Therapeutics Shares Fall 5% After Week 28 ORKA-001 Trial Data

4 hours ago | finance.yahoo.com

Oruka Therapeutics Reports Deepening Responses for ORKA-001 Through Week 28

4 hours ago | marketscreener.comM

Oruka falls after updating mid-stage trial data for plaque psoriasis therapy

4 hours ago | seekingalpha.com

Oruka Reports Positive Week 28 Results For ORKA-001 In Plaque Psoriasis; Stock Down

September 23 at 8:49 AM | rttnews.com

Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing

September 23 at 7:00 AM | globenewswire.com

352,824 Shares in Oruka Therapeutics, Inc. $ORKA Bought by Bank of America Corp DE

September 23 at 3:04 AM | marketbeat.com

Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $51,034.75 in Stock

September 22 at 4:37 AM | insidertrades.com

Oruka Therapeutics Insider Sold Shares Worth $936,417, According to a Recent SEC Filing

September 22 at 1:07 AM | marketscreener.comM

Arjun Agarwal Sells 533 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

September 21 at 7:07 PM | marketbeat.com

Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) CEO Sells $234,680.92 in Stock

September 18, 2026 | americanbankingnews.com

Arjun Agarwal Sells 9,459 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

September 17, 2026 | americanbankingnews.com

Joana Goncalves Sells 7,947 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

September 17, 2026 | americanbankingnews.com

Oruka Therapeutics (NASDAQ:ORKA) SVP Sells 560 Shares

September 16, 2026 | insidertrades.com

Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 560 Shares of Stock

September 15, 2026 | marketbeat.com

Lawrence Otto Klein Sells 2,452 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

September 15, 2026 | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,947 Shares of Stock

September 15, 2026 | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) SVP Sells 9,459 Shares of Stock

September 15, 2026 | marketbeat.com

Oruka (ORKA): EVERLAST-A 28+ Week Data Key Catalyst For ORKA-001 In Psoriasis

September 15, 2026 | rttnews.com

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Recommendation of "Moderate Buy" by Brokerages

September 13, 2026 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORKA, INCY, BNTX, and GMAB Company Descriptions

BioNTech NASDAQ:BNTX

$98.46 -2.41 (-2.39%)

Closing price 04:00 PM Eastern

Extended Trading

$98.77 +0.31 (+0.31%)

As of 06:32 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Genmab A/S NASDAQ:GMAB

$34.75 -0.47 (-1.33%)

Closing price 04:00 PM Eastern

Extended Trading

$33.97 -0.78 (-2.24%)

As of 05:36 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Incyte NASDAQ:INCY

$124.64 -2.29 (-1.80%)

Closing price 04:00 PM Eastern

Extended Trading

$124.60 -0.03 (-0.03%)

As of 06:24 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Oruka Therapeutics NASDAQ:ORKA

$89.93 -4.62 (-4.89%)

Closing price 04:00 PM Eastern

Extended Trading

$89.62 -0.32 (-0.35%)

As of 06:28 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORKA, INCY, BNTX, and GMAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORKA, INCY, BNTX, and GMAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORKA, INCY, BNTX, and GMAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORKA, INCY, BNTX, and GMAB Company Descriptions

BioNTech NASDAQ:BNTX

Genmab A/S NASDAQ:GMAB

Incyte NASDAQ:INCY

Oruka Therapeutics NASDAQ:ORKA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORKA, INCY, BNTX, and GMAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORKA, INCY, BNTX, and GMAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORKA, INCY, BNTX, and GMAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORKA, INCY, BNTX, and GMAB Company Descriptions

BioNTech NASDAQ:BNTX

Genmab A/S NASDAQ:GMAB

Incyte NASDAQ:INCY

Oruka Therapeutics NASDAQ:ORKA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools